Compare Novartis AG (NVS) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Royal Caribbean Cruises Ltd — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Royal Caribbean Cruises Ltd trades at $286.28 (market cap $76.75B). The key difference: Novartis AG is far larger — about 3.8× Royal Caribbean Cruises Ltd's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | RCL | |
|---|---|---|
Market Cap | $290.25B | $76.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $365.84 |
52-Week Low | $113.50 | $246.71 |
Enterprise Value | $330.27B | $98.03B |
Dividend Yield | 3.17% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Royal Caribbean (RCL) trades at $287.90, near its 52-week high, with a modest 0.33% daily gain. The stock shows strong fundamental momentum, with revenue growing from $8.8B in 2022 to $17.9B in 2025 and net income surging to $4.3B. However, technical indicators signal a bearish trend, with moving averages and oscillators pointing to near-term pressure. Recent news highlights earnings anticipation and board appointments, while analyst consensus remains bullish with a $328 price target.
The outlook for RCL is positive based on robust earnings growth and expanding profit margins, but risks include high debt levels and potential economic sensitivity. Investor sentiment is mixed, with technical weakness offset by strong fundamentals. The stock presents a long-term opportunity if it can maintain operational execution amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
